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INTRODUCTION
T he cornea is a transparent tissue. Corneal scarring that results from trauma, mechanical injury, infection, or surgery is a leading cause of blindness worldwide, affecting a total of 7 to 10 million people [1] . Corneal transplantation remains the standard strategy for corneal blindness therapy. However, the clinical reach of corneal transplantation is limited by the supply of donor corneas, and its effectiveness can be compromised by postsurgical complications such as graft failure and rejection [2] . There are currently no effective topical treatments for corneal scarring, and the development of new therapies is thus a clinical priority. More than 90% of the total cornea is composed of stroma. The current theories regard the corneal stroma as being primarily responsible for the transparency of the cornea. Stromal injury may lead to wound healing. This healing is essentially a series reactions at the cellular and biochemical levels that are characterized by inactive fibroblast activation, migration, and proliferation, as well as extracellular matrix (ECM) synthesis and contraction [3] . However, corneal scarring, a severe complication of corneal injury, could be caused by inordinate stroma contraction at the wound site. Previous studies showed that transforming growth factor beta (TGF-β) significantly affects corneal fibrosis and scarring [4] [5] , with TGF-β signal transduction thus being a promising target of developing anti-fibrotic therapies. The disruption of TGF-β signaling by the targeted delivery of the inhibitory protein Smad7 with a recombinant adeno-associated virus injected into the corneal stroma has been found to attenuate the incidence of corneal haze after photorefractive keratectomy (PRK) in a rabbit model of corneal injury [6] . Treatment with cationic nanoparticles complexed with a combination of three small interfering RNAs targeting TGF-β and its receptor mRNAs also inhibited the occurrence of corneal haze in an in vitro model of rabbit cornea culture [7] . Tranilast, or N-(3',4'-dimethoxycinnamoyl)-anthranilic acid, is used as an anti-allergic medicine that is widely applied for the administration in allergic diseases (e.g. allergic conjunctivitis, bronchial asthma, and hypertrophic scars) [8] . It also exerts an anti-fibrotic effect by inhibiting TGF-β functions. Tranilast attenuated the development of diastolic dysfunction and histopathological characteristics of experimental diabetic cardiomyopathy by inhibiting TGF-β-induced protein kinase phosphorylation [9] . The topical application of tranilast was also shown to attenuate the development of corneal haze after PRK [10] and to prevent postoperative adhesion after strabismus surgery [11] in rabbit models by suppressing TGF-β expression.
Given that corneal fibroblast-mediated collagen contraction is involved in corneal scarring and the loss of corneal transparency, using an in vitro model, we investigated if tranilast has effects on human corneal fibroblast (HCF)-mediated collagen gel contraction in stimulation with TGF-β. Moreover, we tested the effects of tranilast on myosin light chain (MLC) and paxillin phosphorylation, the secretion of tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs), as well as the development of focal adhesions and actin stress fibers in these cells. according to the principles of the Declaration of Helsinki for research involving human subjects. Cell isolation and culture were performed as described [12] . In brief, after mechanically removing the endothelial layer of the cornea, the remaining tissue was incubated with 2 mg/mL of dispase in MEM at 37℃ for 1h. The single-cell suspension of HCFs was achieved by mechanically removing the epithelial layer and treating with 2 mg/mL of collagenase in MEM at 37℃. The cells were maintained in MEM added with 10% FBS and were incubated at 37℃ under 5% (vol/vol) CO 2 . Three individual donors' cells were employed. Three to seven passages were used for the present study. Collagen Gel Contraction Assay Collagen gel was prepared as described elsewhere [12] . Reconstitution buffer, 3 mg/mL of type I collagen, 10×MEM, and 1.1×10 6 cells/mL of HCF suspension were combined at the ratio of 1:7:1:2 (vol/vol/vol/vol) on ice. The mixture was equally (0.5 mL) added into a 24-well culture plate that was pre-coated with 1% BSA. A microspatula was used to free the collagen gels and solidified mixture from the sides of the wells. TGF-β or tranilast in 0.5 mL serum-free MEM was added onto the top of each gel. A ruler was used daily to measure the diameter of the gels, and gel contraction was calculated at every time point by subtracting the baseline diameter. Each measurement was triplicated and averaged. Immunoblot Analysis Following a previous protocol, immunoblot analysis was performed [13] . For paxillin and MLC, ice-cold lysis buffer was used to lyse collagen gel/HCFs culture, and 10 μg protein of the lysates were subjected to SDSpolyacrylamide gel electrophoresis (PAGE). For TIMP-1, TIMP-2, MMP-1, and MMP-3, culture supernatants were fractionated by SDS-PAGE. The proteins were separated and transferred onto a nitrocellulose membrane. The following blocking was performed in 5% nonfat milk at room temperature for one hour. The specific primary antibodies (1:1000 dilution) were incubated at 4℃ for overnight. Then, the membrane was washed extensively with Tris-buffered saline with Tween-20. Horseradish peroxidase-conjugated secondary antibodies were incubated at room temperature for one hour and detected by ECL reagents. The intensity of the immunoreactive bands was measured by ImageJ (NIH, Bethesda, MD, USA). Gelatin Zymography According to the previous study, gelatin zymography for culture supernatants was performed [14] . A mixture of culture supernatant (8 μL) and nonreducing SDS sample buffer (4 μL) were applied to SDS-PAGE (0.1% gelatin) at 4℃. The gel then went through the following process: primary incubation in 2.5% Triton X-100 at room temperature for 1h, secondary incubation in a reaction buffer of 1% Triton X-100, Tris-HCl (50 mmol/L), and CaCl 2 (5 mmol/L) for 18h at 37℃, and final staining with 0.5% Coomassie brilliant blue. Fluorescence Microscopy According to a described protocol, F-actin staining and phosphotyrosine of HCFs cultured in collagen gel were performed [13] . Fixation of HCFs in collagen gels were performed by applying 1% paraformaldehyde in phosphate-buffered saline (PBS) for half an hour at room temperature, allowed to dry, and then permeabilized by 1% Triton X-100 in PBS for another half hour. After 1% BSA blocking, the cells were incubated for 1h with antiphosphotyrosine (1:
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200 dilution) antibody at room temperature and then incubated with Alexa Fluor 488-conjugated secondary antibody (1:1000 dilution) for a half hour. Finally, the cells were incubated with 1:200 diluted phalloidin (Alexa Fluor 568-conjugated) for a half hour for F-actin staining and incubated with 1:3000 diluted TOTO-3 iodide for 10min for nuclei staining. A confocal scanning laser microscope (Axiovert200M; Carl Zeiss, Japan) was used for imaging. Statistical Analysis Quantitative data are expressed as means±standard deviation (SD). The experiments were performed at least three times (triplicated for each independent experiment). Significant differences were determined using Dunnett's multiple comparison test or the Tukey-Kramer test. A significant level of P value of 0.05 was used for all statistical tests.
RESULTS Effect of Tranilast on Human Corneal Fibroblastsmediated Collagen Gel Contraction Induced by TGF-β
To investigate if tranilast can affect collagen contraction mediated by HCFs, we employed a three-dimensional collagen gel for cell culture with or without 1 ng/mL of TGF-β as well as several concentrations of tranilast for various durations. In our 3-day incubation with tranilast at a range of 30 to 300 μmol/L, the inhibition of TGF-β-stimulated gel contraction by tranilast was dose-dependent. We observed a statistically significant effect that started from 100 μmol/L and maximized at 300 μmol/L (Figure 1 ). This effect of 300 μmol/L tranilast was also duration-dependent and became statistically significant at day 2 ( Figure 2) .
Effects of Tranilast on TGF-β-induced Stress Fibers and Focal Adhesion Formation in Human Corneal Fibroblasts
The 3-day cell culture in collagen gels with no TGF-β contained no stress fibers and exerted a dendritic morphology and few phosphotyrosine-specific fluorescence signals ( Figure  3A-3C ). Cells cultured with TGF-β exhibited actin stress fibers accompanied with phosphotyrosine immunofluorescence in a punctate pattern. The merged fluorescence signal of F-actin and phosphotyrosine implied that stress fiber formation may correlate with phosphotyrosine expression (Figure 3E-3G) . However, compared with cells only stimulated by TGF-β, the group exposed to TGF-β and treated with 300 μmol/L of tranilast showed a relatively normal morphology with less stress fiber formation and focal adhesions ( Figure 3I-3K) . The negative control of normal mouse IgG staining confirmed the specificity of phosphotyrosine staining ( Figure 3D, 3H) .
Effects of Tranilast on Paxillin and Myosin Light Chain Phosphorylation in Human Corneal Fibroblasts
The phosphorylation of paxillin ( Figure 4 ) and MLC ( Figure 5 ) in HCFs can be induced by TGF-β. The phosphorylation was concentration-dependently inhibited by tranilast. The 300 μmol/L of tranilast also inhibited the total paxillin expression (Figure 4 ) without exerting an effect on the total expression of MLC ( Figure 5 ). revealed that TGF-β increased the release of MMP-1 and MMP-3 in culture. The secretion of these proteins was sensitively and dose-dependently inhibited by tranilast. In supernatant gelatin zymography, the amounts of the pro and active forms of MMP-2 were significantly increased by TGF-β. However, the effect was suppressed by tranilast at 300 μmol/L. TGF-β minimally stimulated the release of TIMP-2 from HCFs, which was not inhibited by tranilast (Figure 6 ).
Effects of Tranilast on the Secretion of MMPs and TIMPs by Human Corneal Fibroblasts Immunoblot analysis

DISCUSSION
The current study revealed that tranilast inhibited the HCFsmediated collagen gel contraction induced by TGF-β in a doseand duration-dependent manner. Tranilast also attenuated TGF-β-stimulated paxillin and MLC phosphorylation, as well as focal adhesion and stress fiber formation. In addition, tranilast inhibited the secretion of MMP-1, MMP-2, as well as MMP-3 by HCFs stimulated by TGF-β. Vol. 11, No. 8, Aug.18, 2018 www.ijo.cn Tel:8629-82245172 8629-82210956 Email:ijopress@163.com
Tranilast inhibition of corneal fibroblast contraction
Cornea transparency is largely contributed by the stroma, which consists of ECM (mainly type I collagen) and keratocytes. Corneal fibroblast-mediated ECM contraction is required for wound closure during the normal wound healing process [15] .
However, excessive contraction may result in the development of corneal scarring and the consequent loss of tissue clarity. Floating three-dimensional collagen gels have been adopted as a model for studies of fibrosis and tissue contractility. TGF-β plays a crucial role in corneal fibrosis. In the current study, we demonstrated that tranilast alleviated the contraction of collagen gel under the stimulation of TGF-β, which was mediated by HCFs with dose-and duration-dependent characteristics. Corneal haze after photorefractive keratectomy can be inhibited by topical tranilast through down-regulating TGF-β1 expression in keratocytes [10] . Additionally, 0.5% tranilast ophthalmic solution instillation was effective in preventing adhesion and fibrosis after strabismus surgery [11] .
The present results implied that tranilast could also effectively prevent or treat corneal scarring through its inhibitory action on the contractility of corneal fibroblasts. Cell contractility has been reported to be enhanced by TGF-β stimulation. The mechanisms include focal adhesion activation and actin microfilaments polymerization and reorganization [13] . Another study showed that actin stress fibers formation and the activation of adhesion molecules related to integrin-ECM interactions could contribute to the contraction of collagen gel mediated by HCFs [12] . We have now shown that TGF-β-stimulated actin stress fibers and focal adhesion formation in HCFs can be inhibited by tranilast. By activating both serinethreonine and tyrosine kinases signaling pathways, TGF-β induces downstream molecule phosphorylation [16] . Paxillin, a focal adhesions component, takes tyrosine phosphorylation under the TGF-β stimulation [17] . The phosphorylation of MLC further enhances stress fiber formation as well as actomyosin contraction [18] . Based on our current data, we demonstrated that tranilast suppressed TGF-β-induced paxillin and MLC phosphorylation in HCFs cultured in collagen gels. Thus, partly due to the inhibition of paxillin and MLC phosphorylation, tranilast alleviated the focal adhesion formation and stress fibers induced by TGF-β. The effects of tranilast could also inhibit the fibrotic tissue contraction in corneal scarring. TGF-β induces fibrosis both by eliciting cellular transdifferentiation and modulating MMP activity [19] . MMPs are calcium-dependent zinc-containing endopeptidases. They can target the ECM components to up-regulate the expression of the enzymes that are associated with inordinate scarring at the ocular surface [20] . MMPs have been proven to be involved in wound contraction and matrix reorganization. They have exhibited important functions during wound healing [21] [22] . An animal study showed that the inhibition of MMPs could reduce matrix contraction and limit subconjunctival scarring [23] . Various studies have also demonstrated that TGF-β up-regulates MMP-1, MMP-2, and MMP-3 expression [14, [24] [25] . We found that tranilast attenuated the release of these MMPs in HCFs induced by TGF-β, implying that the inhibiting effects of tranilast on TGF-β-induced collagen gel contraction could also be caused by similar mechanisms. In summary, we have shown that tranilast inhibited the HCF contraction induced by TGF-β by suppressing actin stress fibers formation, focal adhesions formation, and MMPs release. Therefore, tranilast may effectively inhibit corneal scarring by attenuating corneal fibroblast contractility.
